Literature DB >> 30562906

Perceived Fatigue in Spinal Muscular Atrophy: A Pilot Study.

Sally Dunaway Young1,2, Jacqueline Montes1,3, Samantha S Kramer1, Bernadette Podwika3, Ashwini K Rao3, Darryl C De Vivo1.   

Abstract

BACKGROUND: Fatigue is a common complaint in spinal muscular atrophy (SMA). Fatigability is well described in ambulatory SMA but the relationship to perceived fatigue has not been evaluated. Understanding this relationship has proven challenging for most disorders.
OBJECTIVE: To assess the relationship of perceived fatigue to fatigability, function, and quality of life in SMA.
METHODS: Thirty-two participants with SMA (21.9% type 2, 78.1% type 3) were recruited. Perceived fatigue and fatigability, function, and quality of life were assessed using standardized questionnaires and assessments. Associations were analyzed using Pearson correlation coefficients (p = 0.05). Also, the effects of age, type, and ambulatory status were determined on perceived fatigue.
RESULTS: All SMA participants reported fatigue. Perceived fatigue was not associated with function, quality of life, or fatigability in ambulatory SMA patients. Neither age, type, nor ambulatory status influenced perceived fatigue.
CONCLUSIONS: Perceived fatigue can be quantified in SMA. Interestingly, perceived fatigue did not correlate with fatigability or function, suggesting that cognitive, homeostatic, or psychologic factors may be more relevant as co-morbid factors. Clinical trials targeting perceived fatigue in SMA should focus on these patient-reported assessments. A multilevel approach is required to separate the various mechanisms involved in perceived fatigue.

Entities:  

Keywords:  Spinal muscular atrophy; clinical trials; fatigability; fatigue; patient reported outcomezzm321990measure; perceived fatigue

Year:  2019        PMID: 30562906     DOI: 10.3233/JND-180342

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  11 in total

1.  Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.

Authors:  Silvia Bonanno; Riccardo Zanin; Luca Bello; Irene Tramacere; Virginia Bozzoni; Luca Caumo; Manfredi Ferraro; Sara Bortolani; Gianni Sorarù; Mauro Silvestrini; Veria Vacchiano; Mara Turri; Raffaella Tanel; Rocco Liguori; Michela Coccia; Renato Emilio Mantegazza; Tiziana Mongini; Elena Pegoraro; Lorenzo Maggi
Journal:  J Neurol       Date:  2022-01-03       Impact factor: 4.849

Review 2.  Spinal muscular atrophy.

Authors:  Eugenio Mercuri; Charlotte J Sumner; Francesco Muntoni; Basil T Darras; Richard S Finkel
Journal:  Nat Rev Dis Primers       Date:  2022-08-04       Impact factor: 65.038

3.  Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial.

Authors:  Silvia Bonanno; Riccardo Giossi; Riccardo Zanin; Valentina Porcelli; Claudio Iannacone; Giovanni Baranello; Gary Ingenito; Stanley Iyadurai; Zorica Stevic; Stojan Peric; Lorenzo Maggi
Journal:  J Neurol       Date:  2022-06-28       Impact factor: 6.682

4.  Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy.

Authors:  Jacqueline Montes; Ashley M Goodwin; Michael P McDermott; David Uher; Feliz Marie Hernandez; Kayla Coutts; Julia Cocchi; Margarethe Hauschildt; Kayla M Cornett; Ashwini K Rao; Umrao R Monani; Carol Ewing Garber; Darryl C De Vivo
Journal:  Ann Clin Transl Neurol       Date:  2021-03-31       Impact factor: 5.430

5.  Fatigue in adults with spinal muscular atrophy under treatment with nusinersen.

Authors:  K Kizina; B Stolte; A Totzeck; S Bolz; M Schlag; C Ose; O von Velsen; C Kleinschnitz; Tim Hagenacker
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379

Review 6.  Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy.

Authors:  Didu S T Kariyawasam; Arlene D'Silva; Cindy Lin; Monique M Ryan; Michelle A Farrar
Journal:  Front Neurol       Date:  2019-08-19       Impact factor: 4.003

7.  Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review.

Authors:  Hamish W Y Wan; Kate A Carey; Arlene D'Silva; Steve Vucic; Matthew C Kiernan; Nadine A Kasparian; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2020-03-12       Impact factor: 4.123

8.  Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey.

Authors:  Lisa Belter; Rosángel Cruz; Jill Jarecki
Journal:  Orphanet J Rare Dis       Date:  2020-08-24       Impact factor: 4.123

9.  An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment.

Authors:  Camilla Binz; Olivia Schreiber-Katz; Susanne Petri; Alma Osmanovic; Mareike Kumpe; Gresa Ranxha; Hannah Siegler; Gary Wieselmann
Journal:  J Neurol       Date:  2020-10-07       Impact factor: 4.849

10.  Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada.

Authors:  H J McMillan; B Gerber; T Cowling; W Khuu; M Mayer; J W Wu; B Maturi; K Klein-Panneton; C Cabalteja; H Lochmüller
Journal:  J Neuromuscul Dis       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.